Cinacalcet corrects hypercalcemia in a mouse model for familial hypocalciuric hypercalcemia type 2 (FHH2) caused by a germline loss-of-function G-protein subunit α11 (Gα11) mutation, Asp195Gly. This evidence concerns the gene GNA11 and hypercalcemia disease.